Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 141

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 141
---
 (IFRS) and business earnings per share (non-IFRS): sum total of reconciling items divided by the weighted average number of shares outstanding. (g) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. 2022 business net income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax).

| SANOFIFORM 20-F2024 | 63 |

| PART I                                               |
| ITEM 5. Operating and Financial Review and Prospects |

We define “Business net income” as Net income attributable to equity holders of Sanofi determined under IFRS, excluding the following items: • net income from discontinued operations, including Opella; • amortization and impairment losses charged against intangible assets (other than software and other rights of an industrial or operational nature); • fair value remeasurements of contingent consideration relating to business combinations (IFRS 3), or to divestments of operations meeting the definition of a business; • expenses arising from the remeasurement of inventories following business combinations (IFRS 3) or acquisitions of groups of assets that do not constitute a business within the meaning of paragraph 2b of IFRS 3; • restructuring costs and similar items (presented within the line item Restructuring costs and similar items ) ; • other gains and losses (including gains and losses on major divestments), presented within the line item Other gains and losses, and litigation ; • other costs and provisions related to litigation (presented within the line item Other gains and losses, and litigation ); • (income)/expenses related to financial liabilities accounted for at amortized cost and subject to periodic remeasurement in accordance with paragraph B5.4.6 of IFRS 9 (Financial Instruments); • tax effects related to the items listed above as well as effects of major tax disputes; • the share of profits/losses from investments accounted for using the equity method, except for joint ventures and associates with which Sanofi has a strategic alliance; and • the portion attributable to non-controlling interests of the items listed above. We also report “Business earnings per share” (“Business EPS”), a non-IFRS financial measure we define as “Business net income” divided by the weighted average number of shares outstanding. “Business EPS” was €7.12 for